This study is looking at how a medication called dapagliflozin (Farxiga) affects the heart, lungs, and body chemistry in people with chronic kidney disease (CKD) and a type of heart failure called heart failure with preserved ejection fraction (HFpEF). Researchers want to see if adding dapagliflozin to your usual care can improve heart function, oxygen use, and levels of circulating metabolites (substances created when your body breaks down food, drugs, or its own tissues). You might be eligible if you are 18-85 years old, have an eGFR (a measure of kidney function) between 25-60 ml/min/1.73m2, and show signs of subclinical HFpEF. The study aims to enroll 60 participants, but its current recruitment status is unclear.

Study design

This is an interventional study where half of the 60 participants will receive dapagliflozin for six months, in addition to their standard care.

What's involved

Participants will take a 10mg dapagliflozin tablet once daily for 6 months. Metabolomic testing and cardiac and functional exercise testing will be done at the start and after six months.

Compensation

Not stated in the trial record.

Follow-up

The primary outcomes, including heart function, oxygen consumption, and metabolite levels, are measured at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.